HARVARD BIOSCIENCE INC Form 8-K October 25, 2018

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

\_\_\_\_\_

Form 8-K

\_\_\_\_\_

#### **CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event Reported): October 25, 2018

#### HARVARD BIOSCIENCE, INC.

(Exact Name of Registrant as Specified in Charter)

**Delaware** (State or Other Jurisdiction of Incorporation)

**001-33957** (Commission File Number)

04-3306140

(I.R.S. Employer Identification Number)

84 October Hill Road, Holliston, MA 01746

(Address of Principal Executive Offices) (Zip Code)

(508) 893-8999

(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

).14a-12)
nge Act (17 CFR 240.14d-2(b))
ge Act (17 CFR 240.13e-4(c))
nge Act (

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company [ ]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

#### Item 2.02. Results of Operations and Financial Condition.

On October 25, 2018, Harvard Bioscience, Inc. issued a press release announcing financial results for the three and nine months ended September 30, 2018 and the details of a related conference call to be held at 4:30 PM EST on October 25, 2018. The press release is furnished as Exhibit 99.1 and incorporated herein by reference.

The information in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

#### Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit	Title
Number	<u> 1111e</u>

<u>Press release of Harvard Bioscience, Inc. issued on October 25, 2018.</u>

#### **SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

## HARVARD BIOSCIENCE, INC.

Date: October 25, 2018 By: /s/ JEFFREY A. DUCHEMIN

Jeffrey A. Duchemin Chief Executive Officer

#### **INDEX TO EXHIBITS**

Exhibit Number Description of Exhibit

99.1 Press Release issued by Harvard Bioscience, Inc. on October 25, 2018. d align="center"> M 45,76911/16/200411/16/2014 Common Stock 45,769 \$ 0 1,841,706 D

# **Reporting Owners**

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
ABDUL LADHA 1963 LOUSHEED HIGHWAY COQUITHAM BRITISH COLUMBIA CANADA, A1 0000	X		CEO, President, CFO	

# **Signatures**

Abdul Ladha 03/23/2006

\*\*Signature of Person

\*\*Bate

# **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 5